2677 results about "Physical chemical" patented technology

Support structures for positioning sensors on a physiologic tunnel for measuring physical, chemical and biological parameters of the body and to produce an action according to the measured value of the parameters. The support structure includes a sensor fitted on the support structures using a special geometry for acquiring continuous and undisturbed data on the physiology of the body. Signals are transmitted to a remote station by wireless transmission such as by electromagnetic waves, radio waves, infrared, sound and the like or by being reported locally by audio or visual transmission. The physical and chemical parameters include brain function, metabolic function, hydrodynamic function, hydration status, levels of chemical compounds in the blood, and the like. The support structure includes patches, clips, eyeglasses, head mounted gear and the like, containing passive or active sensors positioned at the end of the tunnel with sensing systems positioned on and accessing a physiologic tunnel.

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.

Particles comprising(a) a supercooled melt of a poorly water-soluble substance and(b) a stabilizing agent,which have a mean particle size of between 30 and 500 nm, and disperse compositions containing them, as administration forms and delivery systems for drugs, vaccines and other biologically active agents such as herbicides, pesticides, insecticides, fungicides, fertilizers, vitamins, nutrition additives and cosmetics.

Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products. SLPs and PBAs are prepared by the following emulsification process: (1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted. (2) Stabilizers are added either to the lipid or bioactive agent and to the aqueous phase or to the aqueous phase only depending on their physicochemical characteristics. Stabilizers may also be added or exchanged after homogenization. (3) Drugs or other bioactive substances to be incorporated into the SLPs may be melted together with the lipids if the physicochemical characteristics of the substance permit or may be dissolved, solubilized or dispersed in the lipid melt before homogenization. (4) The aqueous phase is heated to the temperature of the melt before mixing and may contain for example stabilizers, isotonicity agents, buffering substances, cryoprotectants and/or preservatives. (5) The molten lipid compounds and the bioactive agents are emulsified in an aqueous phase preferably by high-pressure homogenization.

A method of determining the amount of particulate accumulated in a particulate filter, is based on determining possible variations in the spatial distribution and/or physical-chemical properties of the particulate as a function of engine operating conditions and past particulate accumulation in the particulate filter. A number of reference values defining a relationship between the amount of particulate accumulated in the particulate filter and the pressure drop across the particulate filter are mapped, each of the reference values relating to a respective steady engine operating condition in which particulate is accumulated in the particulate filter. In a given engine operating condition, an operating value of the parameter is then determined as a function of the reference value of the parameter relative to the same steady engine operating condition, and of past particulate accumulation in the particulate filter.

Sprayable, anhydrous and physically/chemically stable dermatological/pharmaceutical compositions, well suited for the treatment of a variety of dermatological disorders, notably psoriasis, contain: a) a therapeutically effective amount of a solubilized corticoid, notably dissolved clobetasol propionate; b) a therapeutically effective amount of a solubilized vitamin D derivative, notably dissolved calcitriol; and c) an oily phase which comprises one or more oils; formulated into d), a sprayable and topically applicable, dermatologically/pharmaceutically acceptable vehicle therefor.

The invention discloses a superfine WC-Co cemented carbide containing rare-earth elements and a preparation method thereof, belonging to the technical field of cemented carbide. In the cemented carbide, the weight of WC rigid phase accounts for 85-94% of that of the cemented carbide, the weight of Co binder phase accounts for 5-14% of that of the cemented carbide, the weight of grain growth inhibitor accounts for 0.3-2.0% of that of the cemented carbide, and the weight of the thulium in the rare earth addition accounts for 0.2-1.2% of that of the Co binder phase. The method comprises the following steps: weighing various powder stocks, ball-milling, drying and pelletizing to form a compound; and suppressing and shaping the compound, sintering and cooling to obtain the cemented carbide. The adding mode of nano rare earth oxide or Co-RE composite powder can be implemented easily and conveniently, and the rare earth is diffusely and evenly distributed, thereby facilitating to perform physo-chemical reactions; and the cemented carbide has the advantages of low production cost, stable and enhanced performance and easy implementation, production and application.

This is a method of filtration of a liquid comprising steps of sequential filtration of said liquid through at least one deep bed medium producing at least one first filtrate followed by at least one membrane medium filtration producing at least one second filtrate, wherein said membrane medium is at least periodically within said deep bed media Many types of deep bed and membrane media can be used. The domain of using contact clarification (direct filtration) can be expanded towards greater solids concentration. Operation and backwash, is simplified, continuous filtration becomes possible. Water can be water from natural source water, process water, wastewater, aqueous or non-aqueous suspensions, emulsions, solutions. Treatment can include mechanical interception of suspended particles, chemical, physical chemical, electrochemical, and biological processes. In water and wastewater processing, control over suspended solids, BOD, COD, nitrogen and phosphorus compounds, bacteria and viruses, heavy metals, color, and other constituents can be dramatically improved as compared to conventional processes. The method can be accommodated in new and modified existing treatment systems.

A method for determining a treatment parameter on a haemofiltration device, as well as a haemofiltration device for applying the method, based on the recognition that a determination method known from haemodialysis can, with little modification, be transferred to haemofiltration. To this effect a physical-chemical characteristic of the substitution fluid and of the fluid which is removed from the haemofilter by way of an ultrafiltrate outlet pipe, is determined. Furthermore, this characteristic is acquired before, after or during a change of this characteristic in the substitution fluid, and is evaluated. As a result, the ion dialysance and thus the urea clearance of a haemofiltration device, which can also be operated as a haemodiafiltration device, can be determined.

The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree. The molecules of FA, and most importantly of TFA, remained within collagen. Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110° C. for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products. Finally, prolonged treatment with TFA provides a transparent collagen, which transparency is further enhanced by adding glycosaminoglycans or proteoglycans, particularly hyaluronic acid. All the above treatments could offer a safe and biocompatible collagen-derived material for diverse biomedical uses, by providing a virus or prion-free product.

The invention is a medical implantable device which is coated by the method according to the invention. The surface of the substrate used for the implantable device, in the raw condition, following a cleaning regime and physiochemical pretreatments, is coated using a biomimetic process in a supersaturated calcium phosphate solution (SCPS) to obtain the desired coating coverage and morphology maintaining a ratio of calcium to phosphorus pH, as well as solution temperature plays a major role in yielding precipitation of the proper phase of CaP so that composition, morphologies, crystal structures, and solubility characteristics are optimal for the deposition process. The biomimetic coating adds the attribute of osteoconductivity to the implant device. To maximize bone growth, the implant must also induce bone growth, or possess the attribute of osteoinductivity. This attribute is acquired by the use of therapeutic agents, i.e. bone morphogenic proteins (BMP), growth factors, stem cells, etc. The preparation of the SCPS solution is slightly altered so that during the immersion of the implant in the SCPS, the therapeutic agents are co-precipitated and bonded with the CaP directly on the underlying surface of the implant device. A final dipping process into a BMP solution provides an initial burst of cellular activity. For delivering stem and/or progenitor cell, after drying the dipped solution of BMP, the cells are cultured on the surface of the implant.

The method according to the invention allows the formation of oil and the retention phenomenon in the mother rock to be modelled. Organic matter characterization experiments are used to establish the molecular model (MM) of the initial sample (E). The thermal cracking reaction of this molecular model is reproduced by dynamic molecular simulation computations with a reactive force field (RMD) and validated by comparison with experimental data. The reaction mechanism obtained (SR) allows to carry out a kinetic study (C) by variation of the temperature parameter. The phase equilibria (PES) of the reaction medium are determined at any time from dynamic simulation. The successive phase equilibrium assessments at various progress stages of the cracking reaction allow following the physicochemical evolution (PC) of the thermal maturation of the organic sample studied. The free hydrocarbons (liquid and gaseous) that are not retained in the solid residue can be quantified throughout numerical modelling of the sample maturation; representing, in the sedimentary basins, the hydrocarbons that are not retained in the organic matrix of the mother rock (Q). This quantity can be used as an indicator or an input value for the retention threshold in basin models.

The present invention provides a system and method for measuring physical, chemical and biological properties of a manufacturing system comprising embedding a plurality of RFID sensors in a plurality of corresponding single use components wherein each of the plurality of RFID sensors is configured to provide multi-parameter measurements for at least one single use component from the plurality of single use components, and each of the plurality of RFID sensors is further configured to provide simultaneous digital identification for the single use component and for its respective RFID sensor and further comprises reading the multi-parameter measurements and the digital identification for the plurality of single use components using at least one RFID writer/reader, processing the measurements using a processor, and controlling subsequent process steps by comparing the measurements of at least one parameter to a predetermined value.

The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.

The present invention provides a tnaluronidase. The hyaluronidase can be produced by the strain Streptomyces aitinocidm 77, Exemplary characteristics of the hyaluronidase include specific C-terminal or other amino acid sequences, including full-length sequences, and improved physico-chemical and actix itj properties as compared to known h> alυronidase preparatkiiis. Described are also various uses of the hyaiurυnidasc, including topical administration of the h> aiuronidasc to improve skin penetration of a co-administered active substance.

The invention relates to a unique battery having an active, porous membrane and method of making the same. More specifically the invention relates to a sealed battery system having a porous, metal oxide membrane with uniform, physicochemically functionalized ion channels capable of adjustable ionic interaction. The physicochemically-active porous membrane purports dual functions: an electronic insulator (separator) and a unidirectional ion-transporter (electrolyte). The electrochemical cell membrane is activated for the transport of ions by contiguous ion coordination sites on the interior two-dimensional surfaces of the trans-membrane unidirectional pores. The membrane material is designed to have physicochemical interaction with ions. Control of the extent of the interactions between the ions and the interior pore walls of the membrane and other materials, chemicals, or structures contained within the pores provides adjustability of the ionic conductivity of the membrane.

Disclosed is a pesticide auxiliary agent whose raw material includes (by mass ratio) plant oil 100, auxiliary solvent 0-50, surface active agent 5-55, the auxiliary agent can be made into the dosage forms of oil miscible concentrate, oil solution, hot mist, aerosol, low-volume spraying agent, pesticide, germicidal agent, sterilizing agent, hygienic pesticide and plant growth agent.

A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.